-
Mashup Score: 28
Background Immune-checkpoint inhibitors (ICIs) have showed unprecedent efficacy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). However, not all patients manifest clinical benefit due to the lack of reliable predictive biomarkers. We showed preliminary data on the predictive role of the combination of radiomics and plasma extracellular vesicle (EV) PD-L1 to predict durable response to ICIs. Main body Here, we validated this model in a prospective cohort of patients receiving ICIs plus chemotherapy and compared it with patients undergoing chemotherapy alone. This multiparametric model showed high sensitivity and specificity at identifying non-responders to ICIs and outperformed tissue PD-L1, being directly correlated with tumor change. Short conclusion These findings indicate that the combination of radiomics and EV PD-L1 dynamics is a minimally invasive and promising biomarker for the stratification of patients to receive ICIs.
Source: jeccr.biomedcentral.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Background The majority of women with epithelial ovarian cancer (OvCa) are diagnosed with metastatic disease, resulting in a poor 5-year survival of 31%. Obesity is a recognized non-infectious pandemic that increases OvCa incidence, enhances metastatic success and reduces survival. We have previously demonstrated a link between obesity and OvCa metastatic success in a diet-induced obesity mouse model wherein a significantly enhanced tumor burden was associated with a decreased M1/M2 tumor-associated macrophage ratio (Liu Y et al. Can, Res. 2015; 75:5046–57). Methods The objective of this study was to use pre-clinical murine models of diet-induced obesity to evaluate the effect of a high fat diet (HFD) on response to standard of care chemotherapy and to assess obesity-associated changes in the tumor microenvironment. Archived tumor tissues from ovarian cancer patients of defined body mass index (BMI) were also evaluated using multiplexed immunofluorescence analysis of immune markers. Re
Source: jeccr.biomedcentral.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
September is Ovarian Cancer Awareness Month. In a recent study partially funded by AICR, researchers learned why people with higher BMI have worse outcomes with ovarian cancer. Read the study to understand the link: https://t.co/IkLLEohUkM
-
Validation of multiomic model of plasma extracellular vesicle PD-L1& radiomics for prediction response to IO in NSCLC @ddemiguelperez @ogarrieta @ANaingMD @Al3ssandroRusso @fred_hirsch @AndresFCardonaZ https://t.co/iaAFkeKsSg